Droxidopa Capsule
NDC Package 72205-072-05
Package Information
Droxidopa capsules is droxidopa is used to treat symptoms of low blood pressure when standing, caused by a certain medical condition (neurogenic orthostatic hypotension-NOH). This formulation utilizes a capsule delivery system. Marketed by Novadoz Pharmaceuticals Llc, this product is identified by NDC 72205-072 and is authorized under FDA application ANDA211741.
Identification & Billing
- RxCUI: 1490026 - droxidopa 100 MG Oral Capsule
- RxCUI: 1490034 - droxidopa 200 MG Oral Capsule
- RxCUI: 1490038 - droxidopa 300 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72205 - Novadoz Pharmaceuticals Llc
- 72205-072 - Droxidopa
- 72205-072-05 - 500 CAPSULE in 1 BOTTLE
- 72205-072 - Droxidopa
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (72205-072). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72205-072-05 identifies a specific commercial package of 500 capsule in 1 bottle of Droxidopa, a human prescription drug labeled by Novadoz Pharmaceuticals Llc. This capsule is formulated for oral use and contains droxidopa as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novadoz Pharmaceuticals Llc on February 19, 2021. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Droxidopa is used to treat symptoms of low blood pressure when standing, caused by a certain medical condition (neurogenic orthostatic hypotension-NOH). This medication can lessen symptoms of low blood pressure when standing (orthostatic hypotension), such as dizziness, lightheadedness, or the "feeling that you are about to black out." Droxidopa is used by people whose daily activities are severely affected by this condition, even after other treatments are used (such as support stockings, water bolus). It is thought to work by making the blood vessels become more narrow, which increases blood pressure.
How is this Novadoz Pharmaceuticals Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72205007205. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.